Exelixis, Inc., a biotechnology company, engages in the discovery, development, and commercialization of new medicines to enhance care and outcomes for people with cancer. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. It also offers COTELLIC tablets, an inhibitor of MEK in combination with vemurafenib for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma in the United States; and in combination with vemurafenib in other territories, including the European Union, Switzerland, Canada, Australia, and Brazil. Exelixis, Inc. has collaboration and license agreement with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, Daiichi Sankyo Company Limited, and Invenra, Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Industry Commercial physical research
Sub-IndustryBiotechnology
SectorMedical
Phone650-837-7000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$452.48 million
Profitability
Miscellaneous
Employees372
OptionableOptionable
Exelixis (NASDAQ:EXEL) Frequently Asked Questions
What is Exelixis' stock symbol?
Exelixis trades on the NASDAQ under the ticker symbol "EXEL."
How were Exelixis' earnings last quarter?
Exelixis, Inc. (NASDAQ:EXEL) posted its quarterly earnings results on Thursday, November, 1st. The biotechnology company reported $0.41 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.19 by $0.22. The biotechnology company had revenue of $225.40 million for the quarter, compared to analyst estimates of $174.14 million. Exelixis had a net margin of 49.53% and a return on equity of 55.71%. The firm's revenue for the quarter was up 47.8% on a year-over-year basis. During the same quarter last year, the business posted $0.26 EPS. View Exelixis' Earnings History.
When is Exelixis' next earnings date?
What price target have analysts set for EXEL?
9 equities research analysts have issued 12 month price targets for Exelixis' shares. Their predictions range from $19.00 to $40.00. On average, they expect Exelixis' share price to reach $27.00 in the next year. This suggests a possible upside of 19.2% from the stock's current price. View Analyst Price Targets for Exelixis.
What is the consensus analysts' recommendation for Exelixis?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exelixis in the last year. There are currently 1 sell rating, 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Exelixis.
Has Exelixis been receiving favorable news coverage?
Media coverage about EXEL stock has trended very positive recently, according to InfoTrie. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Exelixis earned a coverage optimism score of 3.2 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
Are investors shorting Exelixis?
Exelixis saw a increase in short interest in the month of December. As of December 14th, there was short interest totalling 12,953,127 shares, an increase of 14.5% from the November 30th total of 11,316,263 shares. Based on an average daily volume of 4,171,592 shares, the short-interest ratio is currently 3.1 days. Approximately 4.4% of the shares of the company are short sold. View Exelixis' Current Options Chain.
Who are some of Exelixis' key competitors?
Some companies that are related to Exelixis include Iqvia (IQV), Incyte (INCY), EXACT Sciences (EXAS), Icon (ICLR), PRA Health Sciences (PRAH), Charles River Laboratories Intl. (CRL), Syneos Health (SYNH), BTG (BTGGF), Medpace (MEDP), STARPHARMA HOLD/S (SPHRY), Sorrento Therapeutics (SRNE), Pieris Pharmaceuticals (PIRS), Luna Innovations (LUNA), Anavex Life Sciences (AVXL) and Senomyx (SNMX).
Who are Exelixis' key executives?
Exelixis' management team includes the folowing people:
- Dr. Stelios Papadopoulos, Co-Founder & Chairman (Age 70)
- Dr. Michael M. Morrissey, CEO, Pres & Director (Age 57)
- Mr. Christopher J. Senner, Exec. VP & CFO (Age 50)
- Dr. Peter Lamb, Exec. VP of Scientific Strategy & Chief Scientific Officer (Age 57)
- Mr. Jeffrey J. Hessekiel, Exec. VP, Gen. Counsel & Sec. (Age 49)
Who are Exelixis' major shareholders?
Exelixis' stock is owned by many different of institutional and retail investors. Top institutional investors include Retirement Systems of Alabama (0.13%), Tealwood Asset Management Inc. (0.04%), Louisiana State Employees Retirement System (0.03%), Highland Capital Management LLC (0.02%), Boston Advisors LLC (0.02%) and Oakbrook Investments LLC (0.01%). Company insiders that own Exelixis stock include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jack L Wyszomierski, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Stelios Papadopoulos and Vincent T Marchesi. View Institutional Ownership Trends for Exelixis.
Which institutional investors are selling Exelixis stock?
EXEL stock was sold by a variety of institutional investors in the last quarter, including Tealwood Asset Management Inc., Louisiana State Employees Retirement System and Meeder Asset Management Inc.. Company insiders that have sold Exelixis company stock in the last year include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Stelios Papadopoulos and Vincent T Marchesi. View Insider Buying and Selling for Exelixis.
Which institutional investors are buying Exelixis stock?
EXEL stock was acquired by a variety of institutional investors in the last quarter, including Highland Capital Management LLC, Boston Advisors LLC, Oakbrook Investments LLC, Fox Run Management L.L.C., Retirement Systems of Alabama and Cornerstone Advisors Inc.. View Insider Buying and Selling for Exelixis.
How do I buy shares of Exelixis?
Shares of EXEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Exelixis' stock price today?
One share of EXEL stock can currently be purchased for approximately $22.65.
How big of a company is Exelixis?
Exelixis has a market capitalization of $6.77 billion and generates $452.48 million in revenue each year. The biotechnology company earns $154.22 million in net income (profit) each year or $0.51 on an earnings per share basis. Exelixis employs 372 workers across the globe.
What is Exelixis' official website?
How can I contact Exelixis?
Exelixis' mailing address is 1851 Harbor Bay Parkway, Alameda CA, 94502. The biotechnology company can be reached via phone at 650-837-7000 or via email at [email protected]
MarketBeat Community Rating for Exelixis (NASDAQ EXEL)
MarketBeat's community ratings are surveys of what our community members think about Exelixis and other stocks. Vote "Outperform" if you believe EXEL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EXEL will underperform the S&P 500 over the long term. You may vote once every thirty days.
